drugset / Trial / NCT06517173

Y-3 for Injection in the Treatment of Acute Ischemic Stroke

NCT06517173 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset

Timeline

Start
2024-07-24
Primary completion
2025-04-08
Completion
2025-09-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject loberamisal Small molecule 40 mg Intravenous

Indications